SNMMI: Carson discusses Image of the Year

Jun 11, 2024

AuntMinnie.com spoke with Richard Carson, PhD, from Yale University, at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting about the society's 2024 Image of the Year.

The award was given for a study using a new ultrahigh resolution dedicated brain PET system Carson and colleagues developed called the NeuroExplorer.

Click here for our full SNMMI coverage.

Prostate Imaging2

Treatment paradigm shifting for men with prostate cancer

June 28, 2024

Brain Puzzle Dementia

SNMMI: PET/CT illuminates connection between CVD and cognitive impairment

June 12, 2024

IMV’s Oncology in Diagnostic Imaging Market Outlook Report

IMV’s Oncology in Diagnostic Imaging Market Outlook Report

March 15, 2024

Oliver Sartor, MD

SNMMI: Lu-177 PSMA-617 shines for taxane-naive prostate cancer

June 11, 2024

Treatment paradigm shifting for men with prostate cancer

New imaging and treatment strategies are emerging to prolong the lives of men with metastatic castration-resistant prostate cancer (mCRPC).

June 28, 2024

Prostate Imaging2

SNMMI: PET/CT illuminates connection between CVD and cognitive impairment

By Kate Madden Yee

PET/CT reveals a connection between cardiovascular disease (CVD) and cognitive impairment, according to research presented at SNMMI 2024.

June 12, 2024

Brain Puzzle Dementia

SNMMI: PET-based protocol shows promise in radioligand therapy

By Amerigo Allegretto

A PET-based scout dosimetry protocol can be feasible in treating lesions with yttrium-90 FAPI (Y-90 FAPI) radioligand therapy.

June 12, 2024

Lesion uptake from a patient with a solitary fibrous tumor and its FAP expression on gallium-68 (GA-68)-FAPI-46 (A) and intratherpeutic Y-90-FAPI-46 (B). The panel shows the constructed time activity curve with the three PET/CT measurements.

SNMMI: Lu-177 PSMA-617 shines for taxane-naive prostate cancer

By Erik L. Ridley

The radiopharmaceutical Pluvicto improves survival in patients with metastatic prostate cancer who haven’t undergone taxane therapy.

June 11, 2024

Oliver Sartor, MD

SNMMI: UW advances radioimmunotherapy At-211 production, trials

Alpha-emitting astatine-211 (At-211) may open the door to new targeted radioimmunotherapy for treating blood cancer.

June 11, 2024

Preclinical multiple myeloma studies at the University of Washington, presented during SNMMI 2024, show survival of mice at different intervals and doses of the alpha radioimmunotherapy At-211-CD38. Graphic and caption courtesy of Yawen Li, PhD.

SNMMI: FAPI PET/CT shows promise in breast cancer staging

By Amerigo Allegretto

A study presented at SNMMI suggests that FAPI PET/CT could be suitable for systemic staging of newly diagnosed breast cancer.

June 11, 2024

Clinical stage changed by FAPI PET/CT categorized by F-18 FDG PET/CT in newly diagnosed breast cancer.

SNMMI: Study explores theranostic ‘cocktail’ for colon cancer

An animal study shows the feasibility of an approach in colon cancer that simultaneously uses alpha- and beta-emitting isotopes to target and kill cancer cells.

June 11, 2024

An autoradiography image showing the simultaneous biodistribution of Lutetium-177 and Actinium-225 radionuclides in colon cancer xenografts in mice.

SNMMI: Ultralow dose PET protocol eliminates need for CT

By Kate Madden Yee

A new ultralow dose imaging method used with long axial field-of-view PET scanners produces images with a radiopharmaceutical dose 50 times lower than the standard effective dose.

June 11, 2024

Top row: CT- and LSO-TX-based attenuation maps with their respective percentage relative change (%RC) map. Bottom row: PET images reconstructed using CT- and LSO-TX-based attenuation maps with their respective %RC map. Image and caption courtesy of the SNMMI.

SNMMI: Nuclear medicine experiencing an ‘industrial revolution’

By Erik L. Ridley

Recent growth in nuclear medicine has represented the equivalent of an “industrial revolution" for specialty, according to SNMMI President Helen Nadel, MD.

June 10, 2024

Nadel 666768f41cb5b Thumbnail

SNMMI: Nuclear medicine clinician-scientists need passion, stamina

By Erik L. Ridley

Ora Israel, MD, shares what it takes to succeed as a nuclear medicine clinician-scientist in a video interview at SNMMI 2024.

June 10, 2024

Ora Israel Thumbnail

GE HealthCare highlights new cyclotron at SNMMI 2024

By AuntMinnie.com staff writers

GE HealthCare introduced the MINItrace Magni at the Society of Nuclear Medicine and Molecular Imaging annual meeting (SNMMI) annual meeting, a newly designed, small-footprint cyclotron for in-house production of commercial PET radiotracers.

June 10, 2024

The company's MINItrace Magni in-house cyclotron.

SNMMI taps Urbain as president-elect

By AuntMinnie.com staff writers

Jean-Luc Urbain, MD, PhD, has been named president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

June 10, 2024

Jean Luc Urbain Md Ph D V Pelect Snmmi 2024

Page 1 of 3